遗传性血管的治疗进展:关注当前和未来的选择
Kelsey Uminski1, Dawn Goodyear2, Stephen Betschel3
1Division of Hematology and Hematologic Malignancies, University of Calgary, Calgary, AB, Canada. kelsey.uminski@ucalgary.ca.
Advances in therapy
|October 11, 2025
概括
遗传性血管炎 (HAE) 治疗已经取得了显著的进步,通过减少胀发作来改善生活质量. 未来的疗法旨在为HAE患者提供更简单,个性化的护理.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 遗传学是一种遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 遗传性血管 (HAE) 是一种罕见的遗传性疾病,由于布拉迪基宁的过度生产,导致不可预测的胀.
- HAE发作会影响皮肤,肠道和呼吸道,严重影响患者的生活质量.
研究的目的:
- 审查HAE治疗选择的演变.
- 总结目前HAE治疗的进展,并探索未来的策略.
主要方法:
- 这篇叙事综述分析了HAE疗法的进展情况.
- 它总结了当前的进展,并讨论了新兴的治疗方式.
主要成果:
- 破坏卡利克林-基宁通路的向治疗已经改变了HAE护理.
- 按需治疗可以快速缓解症状;预防策略可以减少发作频率并改善生活质量.
结论:
- 目前正在进行的治疗创新,包括口服药物,生物制剂,RNA疗法和基因编辑,旨在简化HAE管理.
- 未来的战略重点是个性化,以患者为中心的护理,解决对可访问性和可持续性的未满足需求.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
414
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
414
Heart Failure V: Medical Management
195
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
195
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
411
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
411
Peripheral Artery Disease III: Interprofessional Care
215
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
215
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K


